{"id": "c1fmjf", "title": "The Case for Merck ($MRK)", "selftext": "On Thursday (6/20), pharma giant **Merck ($MRK)** will be having its [first Investor Day in 5 years](https://www.barrons.com/articles/merck-first-investor-day-in-5-years-what-to-watch-51560521136). In the time since, Merck has made 11 major acquisitions, 3 of which were in the past 6 months including [Tilos Therapeutics last week](https://www.reuters.com/article/us-tilos-therapeutics-m-a-merck/merck-to-buy-tilos-therapeutics-for-up-to-773-million-idUSKCN1TB19J). Experts have called their R&amp;D and M&amp;A activity a \"[full court press on oncology](https://www.forbes.com/sites/joshuacohen/2019/06/14/mercks-full-court-press-on-oncology/)\" as they bolster their cancer drug pipeline. \n\nIn those 5 years,  [\"Merck\u2019s oncology drugs\u2019 sales have grown from a little under $1 billion in 2014 to $8.24 billion in 2018.] (https://www.forbes.com/sites/greatspeculations/2019/06/07/how-much-can-mercks-oncology-drugs-revenue-grow-over-the-next-three-years/)\" This is a completely different company than when they last spoke to investors and I think the investor day will reflect that. As for forward growth, the oncology drug sales will likely grow at \"[an average annual rate of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021.](https://www.forbes.com/sites/greatspeculations/2019/06/07/how-much-can-mercks-oncology-drugs-revenue-grow-over-the-next-three-years)\"\n\nMerck has had a great 52 weeks so far, up 32% due in part to the success of their miracle cancer drug [Keytruda](https://www.ft.com/content/1fa2e0d6-8322-11e9-9935-ad75bb96c849) which brought in [$7B in 2018](https://www.reuters.com/article/us-merck-co-fda/mercks-keytruda-wins-fda-approval-to-treat-head-and-neck-cancer-idUSKCN1TC17M) and continues to get priority FDA approvals (PDUFA) for various cancers including one for small-cell lung cancer review on Monday. \n\n**Facts on Keytruda:**\n\n*  [Keytruda brought in revenue of $7.17 billion for Merck in 2018 (with limited scope of use, expanding to other cancers)](https://www.reuters.com/article/us-merck-co-fda/mercks-keytruda-wins-fda-approval-to-treat-head-and-neck-cancer-idUSKCN1TC17M)\n* \u201c[Keytruda, Merck\u2019s biggest product, is already approved for use in 15 cancer indications across 10 different tumor types in the United States.](https://finance.yahoo.com/news/mercks-keytruda-wins-fda-nod-123312442.html)\u201d\n* \"[Keytruda has generated \u201csales of $2.27 billion in the first quarter of 2019, up around 5.6% sequentially and 55% year over year. Sales were driven by the launch of indications globally](https://finance.yahoo.com/news/mercks-keytruda-wins-fda-nod-123312442.html)\u201d \n* **[Current cancer types Keytruda used for after FDA approval:](https://www.keytruda.com/#select-your-cancer-type)** advanced non\u2013small cell \nlung cancer,\nmelanoma,\nhead and neck squamous\ncell cancer,\nadvanced urothelial \nbladder cancer,\nadvanced kidney cancer (rcc),\nmicrosatellite instability-\nhigh cancer,\nclassical hodgkin \nlymphoma,\nadvanced gastric cancer,\nadvanced cervical cancer,\nprimary mediastinal b\u2011cell lymphoma,\nadvanced hepatocellular carcinoma,\nadvanced merkel cell carcinoma\n* \"Meanwhile, Keytruda is being studied in phase III studies for breast, cervical, colorectal, esophageal, gastric, hepatocellular, nasopharyngeal, mesothelioma, ovarian, renal and small-cell lung cancers while Lynparza is being evaluated for pancreatic and prostate cancer. Lenvima is being studied in combination with Keytruda for endometrial cancer. ([source](https://finance.yahoo.com/news/keytruda-4-other-reasons-invest-133101602.html))\"\n* [complete history of FDA Keytruda approvals](https://www.drugs.com/history/keytruda.html)\n\n**Here is their busy June since 6/10:**\n\n\n* **6/10: [Acquired Tilos Therapeutics](https://www.marketwatch.com/story/merck-to-buy-cancer-treatment-biotech-tilos-therapeutics-for-up-to-773-million-2019-06-10):** \"Tilos targets therapeutics for the treatment of cancer, fibrosis and autoimmune diseases.\"\n* **6/11: \u201c[FDA has granted approval to its blockbuster PD-L1 inhibitor, Keytruda for first-line treatment of recurrent or metastatic head and neck squamous cell cancer \\(HNSCC\\)](https://finance.yahoo.com/news/mercks-keytruda-wins-fda-nod-123312442.html)\u201d**\n* **6/14: [JP Morgan maintains \u201coverweight\u201d rating, PT $93](https://www.benzinga.com/stock/mrk/ratings)** \n* **6/17: [PDUFA priority review for Keytruda KN-158 \\(Small cell lung cancer \\(SCLC\\)\\)](https://www.biopharmcatalyst.com/calendars/fda-calendar)** \n* Monday's PDUFA review is for Keytruda in patients with small-cell lung cancer (SCLC). Here is a 2017 report on \"[Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer](https://ascopubs.org/doi/full/10.1200/JCO.2017.72.5069)\" that showed \"promising antitumor activity.\" \n* As for non-small-cell lung cancer (SCLC), a [report from November](https://www.nejm.org/doi/full/10.1056/NEJMoa1810865) found the addition of Keytruda to chemotherapy led to \"significantly longer overall survival and progression-free survival than chemotherapy alone.\" \n* **6/19: Interest rate decision**\n* **6/20:[ first investor day in 5 years,](https://www.barrons.com/articles/merck-first-investor-day-in-5-years-what-to-watch-51560521136)** most likely to discuss pipeline, acquisitions, Tilos plans. The 5 years without an investors day leads me to believe the company want to present something promising but who the hell knows. Could be routine investor checkup.\n* \"Analysts are looking for news on Merck\u2019s blockbuster cancer drug Keytruda, other drugs in the Merck pipeline, and the company\u2019s vaccine franchises\"\n* **Sometime over the next few weeks:** World Health Organization (WHO) will declare ebola a global health emergency, it is currently the [second deadliest ebola outbreak in history](https://www.insider.com/second-largest-outbreak-of-ebola-central-africa-has-killed-1400-2019-6). [Merck has the only ebola vaccine currently in use](https://www.devex.com/news/merck-to-make-more-ebola-vaccine-who-declines-to-declare-global-emergency-95114)\n* **7/16:** PDUFA review for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)\n\n**Other Merck products and/or in development:** \n\n* **[New Products Support the Top Line:](https://finance.yahoo.com/news/keytruda-4-other-reasons-invest-133101602.html)** \"Keytruda Lynparza, Gardasil and Bridion are supporting the company\u2019s top line. Key recent approvals for Merck include Steglatro and its fixed-dose combinations for type II diabetes, two new HIV drugs \u2014 Pifeltro and Delstrigo \u2014 containing doravirine and Prevymis (letermovir) for cytomegalovirus (CVM) infection. These new products coupled with successful and regular label expansions for Keytruda and PARP inhibitor, Lynparza (markets in partnership with AstraZeneca AZN) provide incremental sales growth opportunities.\"\n\n* **[A Strong Pipeline:](https://finance.yahoo.com/news/keytruda-4-other-reasons-invest-133101602.html)** \"Merck has many pipeline candidates in advanced stages of development targeting multiple disease areas such as oncology, cardiovascular diseases, diabetes, infectious diseases, neurosciences, respiratory and immunology diseases and vaccines. Merck can gain approval for two new products this year, a vaccine for Ebola Zaire, V920 and an anti-bacterial medicine, MK-7655A, which is a fixed combination of relebactam with imipenem/cilastatin.\"", "created_utc": 1560722799, "permalink": "/r/wallstreetbets/comments/c1fmjf/the_case_for_merck_mrk/", "is_self": true}